These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 18423257)

  • 1. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
    Czernik A; Beutner EH; Bystryn JC
    J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC; Jiao D
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
    Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
    Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N; Bhol KC; Ahmed RA
    Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
    Green MG; Bystryn JC
    Arch Dermatol; 2008 Dec; 144(12):1621-4. PubMed ID: 19075146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients.
    Schmidt E; Dähnrich C; Rosemann A; Probst C; Komorowski L; Saschenbrecker S; Schlumberger W; Stöcker W; Hashimoto T; Bröcker EB; Recke A; Rose C; Zillikens D
    Exp Dermatol; 2010 May; 19(5):458-63. PubMed ID: 20163452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy.
    Aoyama Y; Moriya C; Kamiya K; Nagai M; Rubenstein D; Iwatsuki K; Kitajima Y
    Eur J Dermatol; 2011; 21(1):58-61. PubMed ID: 21233063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia?
    Laffitte E; Panizzon RG; Borradori L
    Dermatology; 2008; 217(4):337-9. PubMed ID: 18799879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
    Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
    Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
    Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.
    Hallaji Z; Mortazavi H; Lajevardi V; Tamizifar B; AmirZargar A; Daneshpazhooh M; Chams-Davatchi C
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):275-80. PubMed ID: 19709345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development?
    Torzecka JD; Woźniak K; Kowalewski C; Waszczykowska E; Sysa-Jedrzejowska A; Pas HH; Narbutt J
    Arch Dermatol Res; 2007 Aug; 299(5-6):239-43. PubMed ID: 17534636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
    Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
    Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of pemphigus autoantibodies by IIF and ELISA tests in patients with pemphigus vulgaris and foliaceus and in healthy relatives.
    Torzecka JD; Narbutt J; Sysa-Jedrzejowska A; Waszczykowska E; Lukamowicz J; Pas HH
    Med Sci Monit; 2003 Dec; 9(12):CR528-33. PubMed ID: 14646976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of sensitivity and specificity of enzyme-linked immunosorbent assay (ELISA) for detecting antidesmoglein 1 and 3 in Thai patients with pemphigus vulgaris and foliaceus.
    Kulkollakarn S; Wattanakrai P; Vachiramon V; Chalidapongse P
    J Med Assoc Thai; 2008 Nov; 91(11):1663-8. PubMed ID: 19127786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
    Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
    Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus.
    Ohyama M; Amagai M; Hashimoto T; Nousari HC; Anhalt GJ; Nishikawa T
    J Am Acad Dermatol; 2001 Apr; 44(4):593-8. PubMed ID: 11260531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of alopecia in patients with paraneoplastic pemphigus].
    Zuo YG; Wang BX; Ma DL; Cao BQ; Zhao JH; Guo Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):354-6. PubMed ID: 16038274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of rituximab in patients with severe pemphigus.
    Schmidt E; Hennig K; Mengede C; Zillikens D; Kromminga A
    Clin Immunol; 2009 Sep; 132(3):334-41. PubMed ID: 19502112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.